# A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Source: https://onco.cc/trials/nct06256588/  
OnCo record `nct06256588` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Dostarlimab in head and neck squamous cell carcinoma, run by GlaxoSmithKline, now recruiting.

## Summary

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma is a phase 3 interventional study registered as NCT06256588 by GlaxoSmithKline, with 864 participants planned, started 2024-03-21 and due to reach its primary completion in 2028-06-30. Interventions recorded: Dostarlimab and Placebo.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06256588
- Phase: 3
- Setting: A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Dostarlimab as Sequential Therapy After Chemoradiation in Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- Sponsor: GlaxoSmithKline
- Enrolled: 864

## Sources

- ClinicalTrials.gov NCT06256588: https://clinicaltrials.gov/study/NCT06256588

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [Dostarlimab](https://onco.cc/drugs/dostarlimab/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/nct06256588.json